Study of an Educational Tool for Adults with Melanoma and Autoimmune Diseases Considering or Receiving Immune Checkpoint Inhibitors

What this Trial Is About

Researchers are studying how well patients with melanoma and pre-existing autoimmune diseases can use a new educational tool designed to help them understand treatment with immune checkpoint inhibitors. This study aims to gather patient opinions on the tools design, ease of use, accessibility, and content to improve educational materials that support future treatment decisions. The study also tests how feasible it is to recruit patients for the study and use the tool in real-world settings. The study has two parts. In Part A, participants will spend 30 to 45 minutes using the educational tool and then take part in a 45-minute interview to share their thoughts about the tools content and format. Part B involves two groups Group I receives standard educational information during their clinical visit and completes questionnaires at baseline, immediately after the visit, and three months later. Group II uses the educational tool for about 20 minutes during their clinical visit and completes the same questionnaires over the same timeframes. Participants will complete interviews or questionnaires to assess their knowledge, decision-making confidence, and feelings such as anxiety, depression, and stress. Researchers will also evaluate the tools acceptability, usability, and how patients perceive its usefulness. These assessments occur immediately after the clinical encounter and up to three months afterward. The study plans to follow key outcomes like decisional conflict for up to four years. Overall, participants will be involved in scheduled visits and surveys over several months to help improve patient education in melanoma treatment.

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors